Fig. 3: Analyses of the NACC clinical scores.
From: Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank
A Bayesian analysis of the NACC clinical scores. There is strong evidence for impairment in the Alzheimer’s disease (AD) score positive group for Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and trails B since the posterior estimate of the effect size lies outside the 95% credible interval, and outside the Region Of Practical Equivalence (ROPE). There is good evidence of no difference for forward and backward digit span since in both cases the distribution of the AD score positive group completely overlaps with the distribution of the AD score negative group. The mean of the AD score negative group is represented by the dotted vertical line with the ROPE denoted by the shaded area on each side. The 75% credible interval is denoted by the thick bars and the 95% credible interval by the thin bars. B Breakpoint analysis of the NACC clinical scores. Disease severity correlated with the AD score positive group (AD score > 0.5) with evidence for a difference in correlation from the AD negative (AD score < 0.5) group in MMSE, MoCA, forward digits span, Trails B, and the Boston naming task.
